PE20030329A1 - Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo - Google Patents
Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismoInfo
- Publication number
- PE20030329A1 PE20030329A1 PE2002000719A PE2002000719A PE20030329A1 PE 20030329 A1 PE20030329 A1 PE 20030329A1 PE 2002000719 A PE2002000719 A PE 2002000719A PE 2002000719 A PE2002000719 A PE 2002000719A PE 20030329 A1 PE20030329 A1 PE 20030329A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- amino
- methyl
- ring
- link
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 title abstract 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- -1 AMINO Chemical group 0.000 abstract 4
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 230000001413 cellular effect Effects 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 abstract 1
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 abstract 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 229960001830 amprenavir Drugs 0.000 abstract 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 230000001351 cycling effect Effects 0.000 abstract 1
- 229960002656 didanosine Drugs 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 150000002430 hydrocarbons Chemical class 0.000 abstract 1
- 229960001936 indinavir Drugs 0.000 abstract 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 229960000884 nelfinavir Drugs 0.000 abstract 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 abstract 1
- 229960001852 saquinavir Drugs 0.000 abstract 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical compound S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960002555 zidovudine Drugs 0.000 abstract 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/16—Eight-membered rings
- C07D313/20—Eight-membered rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001240750 | 2001-08-08 | ||
| JP2002066809 | 2002-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030329A1 true PE20030329A1 (es) | 2003-05-12 |
Family
ID=26620186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000719A PE20030329A1 (es) | 2001-08-08 | 2002-08-07 | Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo |
Country Status (13)
| Country | Link |
|---|---|
| US (7) | US7371772B2 (enExample) |
| EP (3) | EP2206702B1 (enExample) |
| JP (4) | JP4316203B2 (enExample) |
| AR (1) | AR034985A1 (enExample) |
| AT (2) | ATE460406T1 (enExample) |
| AU (1) | AU2002328092A1 (enExample) |
| CA (2) | CA2607992A1 (enExample) |
| DE (1) | DE60235632D1 (enExample) |
| DK (2) | DK1423376T3 (enExample) |
| ES (2) | ES2376855T3 (enExample) |
| PE (1) | PE20030329A1 (enExample) |
| PT (2) | PT1423376E (enExample) |
| WO (1) | WO2003014105A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7371772B2 (en) | 2001-08-08 | 2008-05-13 | Takeda Pharmaceutical Company Limited | Bicyclic compound, production and use thereof |
| JP2004123694A (ja) * | 2002-03-12 | 2004-04-22 | Takeda Chem Ind Ltd | 光学活性スルホキシド誘導体の製造法 |
| US20060160864A1 (en) * | 2003-02-07 | 2006-07-20 | Mitsuru Shiraishi | Acrylamide derivative, process for producing the same, and use |
| EP1593681A4 (en) * | 2003-02-07 | 2007-09-05 | Takeda Pharmaceutical | TRICYCLIC COMPOUND, PROCESS FOR THEIR PREPARATION AND USE |
| EP1593680A4 (en) * | 2003-02-07 | 2008-05-07 | Takeda Pharmaceutical | PYRIDINE DERIVATIVES WITH CONDENSED RING, PROCESS FOR THEIR PREPARATION AND USE |
| WO2005089716A1 (ja) * | 2004-03-24 | 2005-09-29 | Takeda Pharmaceutical Company Limited | 高含量化製剤 |
| EP1728504B1 (en) * | 2004-03-24 | 2013-07-31 | Takeda Pharmaceutical Company Limited | Emulsion stabilizer |
| US20050260139A1 (en) * | 2004-03-30 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on anticholinergics and CCR2 receptor antagonists |
| JP2007269628A (ja) * | 2004-05-28 | 2007-10-18 | Takeda Chem Ind Ltd | 医薬化合物の結晶 |
| EP1825866A4 (en) * | 2004-12-03 | 2008-03-12 | Takeda Pharmaceutical | SOLID PREPARATION |
| US8426387B2 (en) * | 2006-03-31 | 2013-04-23 | Stephen Carper | Treatments for cancer |
| WO2008030853A2 (en) * | 2006-09-06 | 2008-03-13 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| US7846945B2 (en) * | 2007-03-08 | 2010-12-07 | Lexicon Pharmaceuticals, Inc. | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use |
| CA2741060A1 (en) * | 2008-10-17 | 2010-04-22 | Invasc Therapeutics, Inc. | Compositions and methods for treatment of renin-angiotensin aldosterone system (raas)-related disorders |
| MY192644A (en) | 2009-11-27 | 2022-08-29 | Genzyme Corp | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| MX2012011415A (es) | 2010-04-02 | 2013-02-26 | Phivco 1 Llc | Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico. |
| WO2012047630A2 (en) * | 2010-09-27 | 2012-04-12 | Martin Teintze | N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use |
| WO2013024022A1 (en) | 2011-08-12 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| CA2941411A1 (en) * | 2014-03-21 | 2015-09-24 | Tobira Therapeutics, Inc. | Cenicriviroc for the treatment of fibrosis |
| WO2015187663A1 (en) * | 2014-06-02 | 2015-12-10 | Tobira Therapeutics, Inc. | Cenicriviroc for the treatment of hiv-2 infection |
| AU2015314830B2 (en) | 2014-09-12 | 2021-01-07 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| SG11201704837VA (en) | 2014-12-23 | 2017-07-28 | Tobira Therapeutics Inc | Process of making cenicriviroc and related analogs |
| MX2017010277A (es) | 2015-02-10 | 2017-12-07 | Tobira Therapeutics Inc | Cenicriviroc para el tratamiento de la fibrosis. |
| KR101938036B1 (ko) * | 2015-04-16 | 2019-01-14 | 서울대학교산학협력단 | 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법 |
| BR112018076449A2 (pt) * | 2016-06-21 | 2019-04-09 | Tobira Therapeutics, Inc. | cenicriviroc purificado e intermediários purificados para fazer cenicriviroc |
| JP2019526628A (ja) | 2016-08-31 | 2019-09-19 | トビラ セラピューティクス， インコーポレイテッド | セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス |
| JP7086075B2 (ja) * | 2016-12-09 | 2022-06-17 | 南京明徳新薬研発有限公司 | Ｃｃｒ２／ｃｃｒ５受容体拮抗剤としてのビフェニル化合物 |
| CA3051977A1 (en) | 2017-02-24 | 2018-08-30 | Genfit | Pharmaceutical compositions for combination therapy |
| WO2019149089A1 (zh) | 2018-02-02 | 2019-08-08 | 四川科伦博泰生物医药股份有限公司 | 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途 |
| CN111683976B (zh) | 2018-02-05 | 2022-11-18 | 生物辐射实验室股份有限公司 | 具有阴离子交换-疏水混合模式配体的色谱树脂 |
| WO2019238041A1 (zh) * | 2018-06-12 | 2019-12-19 | 南京明德新药研发有限公司 | 一种丙烯酰胺类化合物的晶型及其制备方法 |
| CN113412261A (zh) * | 2019-04-08 | 2021-09-17 | 四川科伦博泰生物医药股份有限公司 | 苯并咪唑化合物、其制备方法及其用途 |
| WO2020259620A1 (zh) | 2019-06-24 | 2020-12-30 | 南京明德新药研发有限公司 | 作为ccr2/ccr5拮抗剂的杂环烷基类化合物 |
| WO2021133811A1 (en) | 2019-12-26 | 2021-07-01 | Teva Pharmaceuticals International Gmbh | Solid state forms of cenicriviroc and process for preparation thereof |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
| EP4159730A4 (en) * | 2020-05-22 | 2024-05-01 | Medshine Discovery Inc. | PYRIDINE DERIVATIVE AND APPLICATION THEREOF |
| CN112472678A (zh) * | 2020-11-12 | 2021-03-12 | 澳美制药厂有限公司 | 肾素那敏制剂及其制备方法 |
| WO2023143112A1 (zh) * | 2022-01-26 | 2023-08-03 | 无锡瓴方生物医药科技有限公司 | 氮杂苯并八元环化合物的盐型、晶型及其应用 |
| WO2024240025A1 (zh) * | 2023-05-22 | 2024-11-28 | 无锡瓴方生物医药科技有限公司 | 一种联合用药物组合物及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62265270A (ja) | 1986-05-13 | 1987-11-18 | Zeria Shinyaku Kogyo Kk | 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤 |
| AU2808495A (en) | 1994-07-04 | 1996-01-25 | Takeda Chemical Industries Ltd. | Phosphonic acid compounds, their production and use |
| RU2167649C2 (ru) | 1995-08-11 | 2001-05-27 | Ниссан Кемикал Индастриз, Лтд. | Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция |
| EP1038525B1 (en) | 1997-10-20 | 2004-07-07 | Dainippon Pharmaceutical Co., Ltd. | Stabilized composition of tetrahydropyrrolo [1,2-a] pyrazine-4-spiro-3'-pyrrolidine |
| WO1999032100A2 (en) * | 1997-12-19 | 1999-07-01 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative |
| EP1104416A2 (en) * | 1998-08-20 | 2001-06-06 | Takeda Chemical Industries, Ltd. | Quaternary ammonium salts and their use as anti-hiv agents |
| CA2244097A1 (en) | 1998-08-21 | 2000-02-21 | Bernard Charles Sherman | Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid |
| EP1140896A1 (en) | 1998-12-21 | 2001-10-10 | Takeda Chemical Industries, Ltd. | Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5 |
| WO2000061109A1 (fr) | 1999-04-12 | 2000-10-19 | Shionogi & Co., Ltd. | Procede de production de composition medicamenteuse renfermant un compose medicamenteux hydrophobe basique |
| JP2001026586A (ja) | 1999-05-07 | 2001-01-30 | Takeda Chem Ind Ltd | 環状化合物およびその用途 |
| CA2384145A1 (en) | 1999-09-06 | 2001-03-15 | Takeda Chemical Industries, Ltd. | Process for the preparation of 2,3-dihydroazepine compounds |
| US7371772B2 (en) * | 2001-08-08 | 2008-05-13 | Takeda Pharmaceutical Company Limited | Bicyclic compound, production and use thereof |
| JP2004123694A (ja) | 2002-03-12 | 2004-04-22 | Takeda Chem Ind Ltd | 光学活性スルホキシド誘導体の製造法 |
| EP1728504B1 (en) * | 2004-03-24 | 2013-07-31 | Takeda Pharmaceutical Company Limited | Emulsion stabilizer |
| WO2005089716A1 (ja) * | 2004-03-24 | 2005-09-29 | Takeda Pharmaceutical Company Limited | 高含量化製剤 |
| EP1825866A4 (en) | 2004-12-03 | 2008-03-12 | Takeda Pharmaceutical | SOLID PREPARATION |
| WO2008030853A2 (en) | 2006-09-06 | 2008-03-13 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| MX2012011415A (es) | 2010-04-02 | 2013-02-26 | Phivco 1 Llc | Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico. |
| CA2818308A1 (en) | 2010-11-18 | 2012-05-24 | Yale University | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus |
| DK2723360T3 (en) | 2011-06-27 | 2017-08-28 | Univ Pierre Et Marie Curie Paris 6 | CCR2 antagonist peptides |
| KR20160013068A (ko) | 2013-05-15 | 2016-02-03 | 토비라 쎄라퓨틱스, 인크. | 세니크리비록 조성물 및 이들을 만들고 이용하는 방법 |
| CA2941411A1 (en) | 2014-03-21 | 2015-09-24 | Tobira Therapeutics, Inc. | Cenicriviroc for the treatment of fibrosis |
| SG11201704837VA (en) | 2014-12-23 | 2017-07-28 | Tobira Therapeutics Inc | Process of making cenicriviroc and related analogs |
| MX2017010277A (es) | 2015-02-10 | 2017-12-07 | Tobira Therapeutics Inc | Cenicriviroc para el tratamiento de la fibrosis. |
-
2002
- 2002-08-07 US US10/484,762 patent/US7371772B2/en not_active Expired - Lifetime
- 2002-08-07 DK DK02762751.2T patent/DK1423376T3/da active
- 2002-08-07 ES ES10150963T patent/ES2376855T3/es not_active Expired - Lifetime
- 2002-08-07 DE DE60235632T patent/DE60235632D1/de not_active Expired - Lifetime
- 2002-08-07 AR ARP020102986A patent/AR034985A1/es not_active Application Discontinuation
- 2002-08-07 DK DK10150963.6T patent/DK2206702T3/da active
- 2002-08-07 CA CA002607992A patent/CA2607992A1/en not_active Abandoned
- 2002-08-07 EP EP10150963A patent/EP2206702B1/en not_active Expired - Lifetime
- 2002-08-07 CA CA2459172A patent/CA2459172C/en not_active Expired - Lifetime
- 2002-08-07 AT AT02762751T patent/ATE460406T1/de active
- 2002-08-07 PE PE2002000719A patent/PE20030329A1/es not_active Application Discontinuation
- 2002-08-07 JP JP2002229532A patent/JP4316203B2/ja not_active Expired - Lifetime
- 2002-08-07 ES ES02762751T patent/ES2339340T3/es not_active Expired - Lifetime
- 2002-08-07 PT PT02762751T patent/PT1423376E/pt unknown
- 2002-08-07 EP EP02762751A patent/EP1423376B1/en not_active Expired - Lifetime
- 2002-08-07 WO PCT/JP2002/008043 patent/WO2003014105A1/en not_active Ceased
- 2002-08-07 EP EP07021230.3A patent/EP1889839B1/en not_active Expired - Lifetime
- 2002-08-07 PT PT10150963T patent/PT2206702E/pt unknown
- 2002-08-07 AT AT10150963T patent/ATE539062T1/de active
- 2002-08-07 AU AU2002328092A patent/AU2002328092A1/en not_active Abandoned
-
2006
- 2006-12-28 JP JP2006355701A patent/JP4358851B2/ja not_active Expired - Lifetime
-
2007
- 2007-10-25 US US11/978,198 patent/US8183273B2/en not_active Expired - Lifetime
-
2008
- 2008-05-12 US US12/119,355 patent/US8362058B2/en not_active Expired - Fee Related
-
2009
- 2009-06-22 JP JP2009147839A patent/JP5275148B2/ja not_active Expired - Lifetime
-
2012
- 2012-05-21 US US13/476,454 patent/US8741943B2/en not_active Expired - Fee Related
-
2013
- 2013-03-13 JP JP2013050937A patent/JP2013136629A/ja active Pending
-
2014
- 2014-04-25 US US14/261,683 patent/US10045968B2/en not_active Expired - Lifetime
-
2018
- 2018-08-08 US US16/058,303 patent/US20190038604A1/en not_active Abandoned
-
2020
- 2020-01-23 US US16/750,977 patent/US20200297700A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003583A1 (es) | Inhibidores de pi3k y métodos de uso de los mismos div 2985-22 | |
| CO2023014807A2 (es) | Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nras | |
| CL2023002276A1 (es) | Inhibidores de cdk y métodos de uso de estos | |
| BR112021022796A2 (pt) | Inibidores de inflamassoma de nlrp3 | |
| BRPI0514692A (pt) | inibidores do receptor sigma | |
| BR112022002496A2 (pt) | Compostos deuterados para uso no tratamento de câncer | |
| CL2025002635A1 (es) | Compuestos inhibidores de pi3ka y uso de los mismos. | |
| BRPI0516132A (pt) | compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica | |
| NI200900053A (es) | Composiciones de fenilalquilamino carbamato | |
| BRPI0412893A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto | |
| CO2020012359A2 (es) | Moduladores calpaína y usos terapéuticos de los mismos | |
| NO20072269L (no) | Arylsulfonamid peri-substituerte bicykliske forbindelser for okklusiv arteriesykdom | |
| BRPI0409928B8 (pt) | composto, composição farmacêutica, uso do composto e processo para a fabricação do mesmo | |
| CO2024012622A2 (es) | Anticuerpos capaces de unirse a la proteína de la espícula de coronavirus sars-cov-2 | |
| MX2024010334A (es) | Composicion farmaceutica que comprende anticuerpo biespecifico anti-ctla4-anti-pd-1 y chiauranib. | |
| CO6430439A2 (es) | Agonistas del receptor de esfingosina -1- fosfato | |
| BR0306927A (pt) | Compostos tricìclicos de 2-pirimidona úteis como inibidores de transcriptase reversa de hiv | |
| BRPI0509912A (pt) | compostos, processo para a preparação dos mesmos, composição farmacêutica, e, uso de um composto | |
| DK1735296T3 (da) | Materialer og fremgangsmåder til behandling af koagulationslidelser | |
| AR128867A1 (es) | Compuestos de pirimid-2-il-prazol como inhibidores de irak | |
| CL2023001268A1 (es) | Composiciones farmacéuticas de un inhibidor de cinasa | |
| EA202191150A1 (ru) | Ингибиторы аминопептидазы а и содержащие их фармацевтические композиции | |
| MX2007001992A (es) | Antagonistas del receptor 5-ht7. | |
| CO5601028A2 (es) | Inhibidores de adhesion celular mediada por integrina alfa 1 beta 2 | |
| BRPI0509667B8 (pt) | composto, processo para a preparação de um composto de fórmula (i), medicamento e uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |